Abstract
Multiple studies have examined the incidence of secondary primary malignancies (SPMs) in gastric cancer patients in Europe and Asia. This retrospective review was conducted to analyze risk of SPM in patients with gastric cancer diagnosed in the United States. We included adult patients diagnosed with gastric cancer from the surveillance, epidemiology, and end result (SEER) 13 database. We calculated the risk of SPMs in these patients using the multiple primary standardized incidence ratio session of SEER*stat software and performed subset analyses of SPM with regard to age, sex, radiotherapy used, and latency period. Among 33,720 patients, 1838 (5.45%) developed 2019 SPMs with an observed/expected (O/E) ratio of 1.11 [95% confidence interval (CI) = 1.06-1.16, p < 0.001] and an absolute excess risk of 18.16 per 10,000 population. The median time to first SPM from the time of diagnosis of gastric cancer was 46.9 months (range 6-239 months). Significant excess risk was observed for gastrointestinal malignancies [O/E ratio 1.71 (CI = 1.59-1.84, p < 0.001)], thyroid [O/E ratio 2.00 (CI = 1.37-2.8, p < 0.001)], and pancreatic cancer [O/E ratio 1.60 (CI = 1.29-21.96, p < 0.001)]. Risk of secondary melanoma, breast cancer, and prostate cancer was lower than in the general population. The risk for SPMs is significantly increased in adults with gastric cancer compared to the general population.
Highlights
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide
Given the global variations in gastric cancer incidence, treatment, and survival, we evaluated the risk of secondary primary malignancies (SPMs) in adult gastric cancer patients in the United States (US) to determine if geographic disparities are present
There are currently more than 13 million cancer survivors in the US, with a projected increase to 18 million by 2022 [10]
Summary
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide. The highest incidences are found in Eastern Asia and Central and Eastern Europe [1]. The majority of patients in the United States (US) present with regional or distant metastases, with an overall 5-year survival rate of 28.3% [1]. Most Japanese gastric cancer patients are diagnosed in early stages of the disease and have an overall 5-year relative survival rate of over 50% [3]. Multiple studies have examined the incidence of secondary primary malignancies (SPMs) in gastric cancer patients in Europe and Asia.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
